Kalshi Biotech Contracts Put FDA and Trial Data Inside CFTC Enforcement Debate

Meta description: Kalshi’s biotech contracts tie FDA and Phase 3 milestones to event markets, raising compliance questions for pharma vendors.

Tags: Kalshi, Polymarket, CFTC, FDA, Merck, AppliedXL

Market platform: Kalshi

Category: Regulation

Kalshi’s July 16 biotech pilot turned selected Phase 3 trial results and FDA decisions into regulated event contracts, creating a new compliance problem for drugmakers and their vendors. The same clinical and regulatory information that can move biotech stocks can now also be used to trade contracts tied directly to approvals, advisory-committee votes and trial endpoints.

The pilot, built with AppliedXL, covers selected late-stage clinical-trial outcomes and FDA regulatory decisions. Kalshi’s launch announcement said the contracts resolve against named public documents, including ClinicalTrials.gov endpoint records, FDA approval letters and advisory-committee vote records. AppliedXL’s public FAQ says the program focuses on selected Phase 3 primary endpoints and FDA decisions, with each contract listing its question, deadline, source documents and resolution criteria before trading begins.

What are Kalshi’s biotech contracts actually pricing?

The contracts are binary event contracts. A trader buys or sells exposure to a defined regulatory or clinical question, and the contract settles according to its listed rules. A trial-endpoint contract may resolve based on whether a named Phase 3 study meets the registered primary endpoint. An FDA approval-by-date contract can resolve based on whether the agency issues an approval letter by the deadline specified in the market rules.

That distinction matters for investors and compliance officers. A “No” outcome on an FDA approval-by-date market does not necessarily mean the drug failed clinically. It can reflect timing, a Complete Response Letter, a missed deadline under the contract terms, or another regulatory outcome that does not satisfy the market’s stated condition. The tradable object is the contract question, not a broad verdict on the drug’s scientific value.

Kalshi’s July 16 announcement named AppliedXL as the resolution-infrastructure partner and said the markets were designed to make drug-development probabilities public. AppliedXL’s FAQ says the pilot lists clinical-trial markets only after enrollment has closed, excludes trials that exclusively enroll patients under 18, and uses predefined public sources for resolution. Those guardrails define the exchange’s starting framework for a sector where material information can sit with many parties before a public announcement.

Why does this matter for drugmakers?

Pharmaceutical companies already manage securities-law risk around clinical data, FDA correspondence and trial readouts. Prediction markets add a different trading venue for the same underlying information. A person with advance access to endpoint data, an advisory-committee outcome or FDA communication may not need to trade the issuer’s stock to profit from the information. A narrowly drafted event contract can isolate the regulatory or clinical milestone itself.

Merck shows why the issue has large-company relevance, even though Kalshi’s initial pilot was not described as a Merck-specific launch. In Merck’s 2024 Form 10-K filed with the Securities and Exchange Commission, the company reported $64.168 billion in total sales and $29.482 billion in Keytruda sales. That made Keytruda about 46% of companywide sales for the year. Merck also told investors in the same filing that it faces patent and regulatory-exclusivity risks across major products, including Keytruda.

That revenue concentration makes clinical and regulatory milestones around oncology portfolios economically important well before any final patent cliff hits. It does not make every pipeline decision a tradable event today, and it does not mean Merck sponsored or requested a prediction market. It does show why large pharmaceutical companies may need to treat event-contract trading as part of their information-control perimeter, especially when a single clinical or regulatory disclosure can move investor expectations.

Who could have material information before the market does?

The risk extends beyond a drugmaker’s own employees. PharmaVoice reported that Mark Scallon, a principal at Baker Tilly, said prediction markets raise compliance stakes for companies and that awareness is the first step. He pointed to third parties in the drug-development chain, including contract research organizations, clinical investigators, study coordinators, central labs, biostatistics firms, technology vendors and consultants.

That list tracks how modern trials operate. Sponsors may own the program, but endpoint data, database locks, statistical analysis, safety updates and regulatory materials can pass through outside vendors before public disclosure. A securities-trading policy aimed only at employees may miss people who have access to the same market-moving information through a services contract.

For smaller biotechnology companies, the exposure can be sharper because a single Phase 3 result or FDA decision can define the company’s valuation. For large pharmaceutical companies, the issue is more distributed: one program may not define the whole company, but a portfolio of late-stage readouts and approval deadlines can still create repeat opportunities for misuse of material nonpublic information.

How has the CFTC treated prediction-market insider trading?

The Commodity Futures Trading Commission has already applied its anti-fraud authority to event-contract trading. On August 28, 2026, the CFTC announced an order filing and settling charges against Gabriel Perez, a White House teleprompter operator, for trading presidential mention-market contracts using material nonpublic information obtained through federal employment. The CFTC said Perez must disgorge $107,539.02, pay a $65,000 civil monetary penalty and accept a three-year trading ban.

The Perez matter did not involve pharmaceutical information. Its relevance is the theory: the CFTC treated event contracts as swaps and alleged that advance access to information about the underlying event could support an enforcement action when used for personal trading. The agency said the trades involved presidential mention markets listed on a prediction-market platform and credited KalshiEX for assistance in the matter.

The Department of Justice has also brought a criminal case tied to prediction-market trading. On May 27, 2026, the U.S. Attorney’s Office for the Southern District of New York announced charges against Google software engineer Michele Spagnuolo, alleging commodities fraud, wire fraud and money laundering. The DOJ said Spagnuolo used confidential Google information to place Polymarket trades and made more than $1.2 million in profits. The complaint’s allegations are now part of the federal criminal case, not a pharma case, but they put corporate confidential information inside the prediction-market enforcement discussion.

The CFTC had already warned the industry. On February 25, 2026, the agency’s Division of Enforcement issued a prediction-markets advisory reminding participants that misuse of material nonpublic information and other market-abuse conduct can fall within the CFTC’s enforcement authority. On March 16, 2026, the CFTC published an advance notice of proposed rulemaking in the Federal Register seeking comment on prediction markets, including questions about inside information, market integrity and events controlled by small groups of people. Comments were due April 30, 2026.

Where does the CFTC rulemaking stand now?

The CFTC moved the rulemaking beyond the March notice before the Perez order. On June 12, 2026, the Federal Register published the agency’s proposal, “Prediction Markets; Public Interest Determinations.” The proposal said the April 30 comment period on the advance notice had closed and that the agency had received and considered roughly 3,500 comments.

That timeline matters for biotech contracts because the policy fight is no longer just a broad request for views. The CFTC has a live rulemaking record on how to evaluate event contracts under public-interest standards, while enforcement staff has separately shown a willingness to pursue trading based on nonpublic information in event markets. For clinical and FDA-linked contracts, those two tracks point to the same question: whether exchange surveillance and general anti-fraud authority are enough for markets built on drug-development events, or whether the agency will impose more specific conditions.

What should pharma compliance teams watch next?

The immediate compliance question is whether drugmakers expand trading policies beyond securities accounts to cover event contracts tied to the company’s trials, regulatory submissions, advisory-committee votes and competitors’ programs where employees or vendors may have confidential information. Existing confidentiality clauses may not expressly mention prediction markets, crypto wallets or event-contract platforms.

Contract language is likely to matter. Sponsors can require CROs, laboratories, investigators, consultants and data vendors to restrict trading in event contracts tied to sponsor programs, maintain logs for personnel with access to key nonpublic data and report suspected misuse. Those controls would mirror familiar information-wall practices from securities compliance, but they would need to account for a market structure where the traded instrument may reference a trial endpoint rather than a stock ticker.

The next regulatory milestone is the CFTC’s action on the June 12, 2026 “Prediction Markets; Public Interest Determinations” proposal. Until the agency finalizes, revises or withdraws that approach, biotech-linked event contracts sit at the intersection of exchange self-certification, CFTC anti-fraud enforcement and pharma compliance programs built for a securities market that no longer captures every tradable drug-development milestone.